Abeona TherapeuticsABEO
ABEO
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Employees: 84
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
22,275% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $16K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
16% more funds holding
Funds holding: 55 [Q3] → 64 (+9) [Q4]
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
3.93% more ownership
Funds ownership: 66.54% [Q3] → 70.47% (+3.93%) [Q4]
6% less capital invested
Capital invested by funds: $182M [Q3] → $171M (-$11.6M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
184%
upside
Avg. target
$15.50
194%
upside
High target
$16
203%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Francois Brisebois 26% 1-year accuracy 9 / 35 met price target | 203%upside $16 | Outperform Initiated | 5 Mar 2025 |
HC Wainwright & Co. Mitchell Kapoor 28% 1-year accuracy 51 / 181 met price target | 184%upside $15 | Buy Reiterated | 19 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m.
Neutral
GlobeNewsWire
1 week ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, March 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 month ago
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona Therapeutics Inc.'s lead program, pz-cel, is an autologous gene therapy for RDEB, showing significant wound healing and pain reduction in clinical trials. Despite a CRL from the FDA, Abeona resubmitted its BLA, with a new PDUFA date set for April 29, 2025. ABEO stock remains undervalued, with potential for significant gains if pz-cel is approved, supported by strong cash reserves and a valuable PRV.
Neutral
GlobeNewsWire
2 months ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 months ago
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025
Neutral
GlobeNewsWire
3 months ago
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona's resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025.
Neutral
GlobeNewsWire
4 months ago
Abeona Therapeutics® Announces Participation in November Investor Conferences
CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024:
Neutral
GlobeNewsWire
4 months ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
4 months ago
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB).
Charts implemented using Lightweight Charts™